📰 Device Designations News
Device Designations News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Device Designations. Real-time updates on events, politics, business and more.
February 8, 2024
PRINCETON, N.J., Feb. 08, 2024 -- CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification,...
January 18, 2024
HemON NL is evaluating the use of ARC-IM® Therapy to address hemodynamic instability after spinal cord injury EINDHOVEN, the Netherlands, Jan. 18, 2024 -- ONWARD Medical N.V. , the medical...
January 17, 2024
CytoSorb Blood Purification Results in Statistically Significant Reductions in Multiple Organ Failure and DysfunctionPRINCETON, N.J., Jan. 17, 2024 -- CytoSorbents Corporation , a leader in the...
December 28, 2023
PRINCETON, N.J., Dec. 28, 2023 -- CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its...
December 28, 2023
CytoSorbents Corporation announced an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board analysis for the...
December 28, 2023
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the pivotal U.S.
December 13, 2023
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood
November 10, 2023
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood
November 9, 2023
Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data analysis completion expected before year-end.PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorptio
October 5, 2023
PRINCETON, N.J., Oct. 05, 2023 -- CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification,...